Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

184 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prospective Multicentric Assessment of 68Ga-DOTANOC PET/CT in Grade 1-2 GEP-NET.
Lugat A, Frampas É, Touchefeu Y, Mirallié É, Bras ML, Senellart H, Rauscher A, Fleury V, Campion L, Rohmer V, Couturier OF, Lebtahi R, Rouzet F, Ruszniewski P, Kraeber-Bodéré F, Bourgeois M, Ansquer C. Lugat A, et al. Among authors: rauscher a. Cancers (Basel). 2023 Jan 14;15(2):513. doi: 10.3390/cancers15020513. Cancers (Basel). 2023. PMID: 36672462 Free PMC article.
Radioimmunotherapy of B-Cell Non-Hodgkin's Lymphoma.
Bodet-Milin C, Ferrer L, Pallardy A, Eugène T, Rauscher A, Alain Faivre-Chauvet, Barbet J, Kraeber-Bodéré F. Bodet-Milin C, et al. Among authors: rauscher a. Front Oncol. 2013 Jul 11;3:177. doi: 10.3389/fonc.2013.00177. eCollection 2013. Front Oncol. 2013. PMID: 23875170 Free PMC article.
A pretargeting system for tumor PET imaging and radioimmunotherapy.
Kraeber-Bodéré F, Rousseau C, Bodet-Milin C, Frampas E, Faivre-Chauvet A, Rauscher A, Sharkey RM, Goldenberg DM, Chatal JF, Barbet J. Kraeber-Bodéré F, et al. Among authors: rauscher a. Front Pharmacol. 2015 Mar 31;6:54. doi: 10.3389/fphar.2015.00054. eCollection 2015. Front Pharmacol. 2015. PMID: 25873896 Free PMC article. Review.
Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial.
Bodet-Milin C, Faivre-Chauvet A, Carlier T, Rauscher A, Bourgeois M, Cerato E, Rohmer V, Couturier O, Drui D, Goldenberg DM, Sharkey RM, Barbet J, Kraeber-Bodere F. Bodet-Milin C, et al. Among authors: rauscher a. J Nucl Med. 2016 Oct;57(10):1505-1511. doi: 10.2967/jnumed.116.172221. Epub 2016 May 26. J Nucl Med. 2016. PMID: 27230928 Free article. Clinical Trial.
68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: Impact on therapeutic decision-making and biomarker changes.
Barbaud M, Frindel M, Ferrer L, Le Thiec M, Rusu D, Rauscher A, Maucherat B, Baumgartner P, Fleury V, Colombié M, Thierry-Morel A, Kraeber-Bodéré F, Campion L, Rousseau C. Barbaud M, et al. Among authors: rauscher a. Prostate. 2019 Apr;79(5):454-461. doi: 10.1002/pros.23751. Epub 2018 Dec 14. Prostate. 2019. PMID: 30549066
Clinical Results in Medullary Thyroid Carcinoma Suggest High Potential of Pretargeted Immuno-PET for Tumor Imaging and Theranostic Approaches.
Bodet-Milin C, Bailly C, Touchefeu Y, Frampas E, Bourgeois M, Rauscher A, Lacoeuille F, Drui D, Arlicot N, Goldenberg DM, Faivre-Chauvet A, Barbet J, Rousseau C, Kraeber-Bodéré F. Bodet-Milin C, et al. Among authors: rauscher a. Front Med (Lausanne). 2019 Jun 4;6:124. doi: 10.3389/fmed.2019.00124. eCollection 2019. Front Med (Lausanne). 2019. PMID: 31214593 Free PMC article. Review.
Preliminary results of a 68 Ga-PSMA PET/CT prospective study in prostate cancer patients with occult recurrence: Diagnostic performance and impact on therapeutic decision-making.
Rousseau C, Le Thiec M, Ferrer L, Rusu D, Rauscher A, Maucherat B, Frindel M, Baumgartner P, Fleury V, Denis A, Morel A, Varmenot N, Debeaupuis E, Campion L, Kraeber-Bodéré F. Rousseau C, et al. Among authors: rauscher a. Prostate. 2019 Sep;79(13):1514-1522. doi: 10.1002/pros.23869. Epub 2019 Aug 17. Prostate. 2019. PMID: 31421657 Clinical Trial.
Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
Rousseau C, Goldenberg DM, Colombié M, Sébille JC, Meingan P, Ferrer L, Baumgartner P, Cerato E, Masson D, Campone M, Rauscher A, Fleury V, Labbe C, Chauvet AF, Fresnel JS, Toquet C, Barbet J, Sharkey RM, Campion L, Kraeber-Bodéré F. Rousseau C, et al. Among authors: rauscher a. J Nucl Med. 2020 Aug;61(8):1205-1211. doi: 10.2967/jnumed.119.236000. Epub 2020 Mar 13. J Nucl Med. 2020. PMID: 32169921 Free PMC article. Clinical Trial.
Promising clinical performance of pretargeted immuno-PET with anti-CEA bispecific antibody and gallium-68-labelled IMP-288 peptide for imaging colorectal cancer metastases: a pilot study.
Touchefeu Y, Bailly C, Frampas E, Eugène T, Rousseau C, Bourgeois M, Bossard C, Faivre-Chauvet A, Rauscher A, Masson D, David A, Cerato E, Carlier T, Sharkey RM, Goldenberg DM, Barbet J, Kraeber-Bodere F, Bodet-Milin C. Touchefeu Y, et al. Among authors: rauscher a. Eur J Nucl Med Mol Imaging. 2021 Mar;48(3):874-882. doi: 10.1007/s00259-020-04989-3. Epub 2020 Aug 21. Eur J Nucl Med Mol Imaging. 2021. PMID: 32820369
Head-to-Head Comparison of 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT in Patients With Midgut Neuroendocrine Tumors.
Ansquer C, Touchefeu Y, Faivre-Chauvet A, Leux C, Le Bras M, Régenet N, Fleury V, Maucherat B, Senellart H, Guyetant S, Carlier T, Scotet-Cérato E, Rauscher A, Frampas E, Kraeber-Bodéré F. Ansquer C, et al. Among authors: rauscher a. Clin Nucl Med. 2021 Mar 1;46(3):181-186. doi: 10.1097/RLU.0000000000003450. Clin Nucl Med. 2021. PMID: 33315677
184 results